Drug Profile

ABI M301

Alternative Names: ABI-M301

Latest Information Update: 28 Feb 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Assembly Biosciences
Developer AbbVie; Assembly Biosciences
Class Anti-inflammatories; Bacteria
Mechanism of Action Gastrointestinal microbiome modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

No development reported Crohn's disease

Most Recent Events

28 Feb 2022 No recent reports of development identified for preclinical development in Crohn's-disease in USA (PO)
18 Jun 2020 ABI M301 is available for licensing as of 18 Jun 2020. https://www.assemblybio.com/collaborations/
18 Jun 2020 Assmebly Biosciences plans to regain worldwide license of ABI M301 from AbbVie in fourth quarter of 2020

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com